A Study of GLWL-01 in Patients With Prader-Willi Syndrome

Overview

The aim of this study is to evaluate efficacy, safety, and pharmacokinetics of GLWL-01 in the treatment of patients with Prader-Willi Syndrome (PWS).

Full Title of Study: “A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: June 12, 2019

Detailed Description

Participants will be assigned to one of two treatment sequences (GLWL-01/Placebo or Placebo/GLWL-01), with each sequence consisting of two treatment periods separated by a washout period

Interventions

  • Drug: GLWL-01
    • Oral administration of 3 capsules, twice a day
  • Drug: Placebo
    • Oral administration of 3 capsules, twice a day

Arms, Groups and Cohorts

  • Other: Treatment Sequence 1
    • GLWL-01 (450mg) twice a day/ Placebo
  • Other: Treatment Sequence 2
    • Placebo / GLWL-01 (450mg), twice a day

Clinical Trial Outcome Measures

Primary Measures

  • Post-treatment Total Score on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT)
    • Time Frame: Up to approximately 4 weeks of double-blind treatment
    • GLWL-01 compared with placebo on the post-treatment HQ-CT score. Total range of score of zero to 36, with higher score indicating a worse outcome.

Secondary Measures

  • Number of Participants With One or More Treatment Emergent Adverse Events (AEs) or Any Serious AEs
    • Time Frame: Baseline up to approximately 18 weeks
    • Evaluate the safety and tolerability of GLWL-01
  • Caregiver Global Impression of Change (CGIC)
    • Time Frame: Up to approximately 4 weeks of double-blind treatment
    • GLWL-01 compared with placebo in the CGIC. Score ranges from 1 to 7, with larger number indicating a worse outcome.
  • Area Under the Concentration Versus Time Curve From Time Zero to 12 Hours (AUC0-12)
    • Time Frame: Day 14 and Day 42, pre-dose, and 0.5, 1, 2, 4, 6, and between 8 and 12 hours postdose
    • Pharmacokinetics (PK) after single and multiple oral dosing
  • Maximum Observed Drug Concentration (Cmax)
    • Time Frame: Day 14 and Day 42, pre-dose, and 0.5, 1, 2, 4, 6, and between 8 and 12 hours postdose
    • Pharmacokinetics after single and multiple oral dosing

Participating in This Clinical Trial

Inclusion Criteria

  • Confirmed diagnosis of PWS based on genetic confirmation using DNA method – Body mass index (BMI) of 27 to 60 kg/m2 – No evidence of weight excursion beyond 10% of baseline weight – Patients must provide assent and have a reliable caregiver (must have been caring for the patient for at least 6 months) who provides a separate written informed consent to participate. The caregiver is expected to be the primary caregiver throughout the study and must be in frequent contact with the patient (defined as at least 4 awake hours per day). The caregiver must be able to communicate with site personnel and in the investigator's opinion must have adequate literacy to complete questionnaires. If a caregiver cannot continue, 1 caregiver replacement is allowed – Are on a stable diet and exercise regimen for >2 months prior Exclusion Criteria:

  • Current enrollment in or discontinuation within the last 30 days from a clinical trial involving any investigational drug or device – Are currently living in a group home for more than 50% of the time – A history or presence of other medical illness that indicates a medical problem that would preclude study participation – Have an estimated glomerular filtration rate <60 mL/minute/1.73 m2. Have macroalbuminuria (defined as spot urine albumin to creatinine ratio of >300 μg/mg) or hematuria – Are hypertensive (defined as sitting systolic blood pressure (BP) greater than or equal to (≥)140 millimeters of mercury (mmHg) and diastolic BP ≥90 mmHg) – Patients on weight loss medications within 30 days of dosing, or with a history of bariatric surgery – Unable to refrain from or anticipates the use of: 1. Any drugs known to be significant inhibitors of Cytochrome P450, family 3, subfamily A (CYP)3A enzymes and/or P-glycoprotein (P-gp) including regular consumption of grapefruit or grapefruit juice for 14 days prior to the first dose. Acetaminophen (up to 2 grams per 24-hour period) may be permitted 2. Any drugs known to be significant inducers of Cytochrome P450, family 3, subfamily A (CYP3A) enzymes and/or P-gp, including St. John's Wort 3. Any medications that prolong the QT/QTc interval, unless the participant has been stable on the medication for at least 3 months and has a corrected QT interval (QTc) <450 msec – Currently taking simvastatin >10 mg per day, atorvastatin >20 mg per day, or lovastatin >20 mg per day, or have a history of statin-induced myopathy/rhabdomyolysis – Unsuitable for inclusion in the study in the opinion of the investigator

Gender Eligibility: All

Minimum Age: 16 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • GLWL Research Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Study Director, Study Director, GLWL Research Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.